Evidence map›Paper›PMID 30538261›Full record

ArticleBritish journal of cancer2019

Desperately seeking…Models to find the right partner and the best use for checkpoint inhibitors.

Francesco Bertolini

Erratum issuedAbstract readEditorialComment
In one paragraph

Article in British journal of cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Engineering neoantigen vaccines to improve cancer personalized immunotherapy.International journal of biological sciences · 2022
    Review
  2. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author.

Francesco BertoliniLaboratory of Hematology-Oncology, European Institute of Oncology, Milan, Italy. francesco.bertolini@ieo.it.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immune checkpoint inhibitors have shown unprecedented clinical activity in a variety of cancer types, but only in a fraction of patients. Promising in vivo synergies have been demonstrated between checkpoint inhibitors and other drugs and/or chemotherapy or radiotherapy, and effective models are now needed to select the best combinatorial regimen and disease setting.

Indexed as

Kidney NeoplasmsNeoplasms, Second PrimaryAnimalsB7-H1 AntigenHumansImmunotherapyMiceB7-H1 Antigen

Identifiers

PMID30538261
PMCPMC6342965

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.